LexDanaLexDanabeta
Inventor

Gwan Sun Lee

Inventor
Seoul, KR

Overview

65→
Patents
2000–2019
Patent span
Human necessities
Primary field (CPC A)

Patents· 65 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07DHeterocyclic compounds20%
A61KPreparations for medical, dental or toiletry purposes17%
C07KPeptides14%
C07HSugars6%
C12NMicroorganisms or enzymes3%
Y02PClimate change mitigation technologies in the production or processing of goods3%
C07JSteroids1%
A47JKitchen equipment1%
A61BDiagnosis1%
PatentTitleYear
10,272,159IgG Fc fragment for a drug carrier and method for the preparation thereof201910,071,166Protein complex using an immunoglobulin fragment and method for the preparation thereof201810,071,171Polypeptide complex comprising non-peptidyl polymer having three functional ends20189,750,820'IgG Fc fragment for a drug carrier and method for the preparation thereof'20179,636,420'Polypeptide complex comprising non-peptidyl polymer having three functional ends'20179,422,349'N-terminal modified exendin-4'20168,957,196'Vector and expression cell line for mass production of recombinant protein and a process of producing recombinant protein using same'20158,895,281'Method for preparing a site-specific physiologically active polypeptide conjugate'20148,846,699'Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof'20148,846,874'IgG Fc fragment for a drug carrier and method for the preparation thereof'20148,822,650'Method for the mass production of immunoglobulin constant region'20148,637,700'Method for preparing (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used therefor'20148,624,026'Method of preparing sitagliptin and intermediates used therein'20148,586,752'Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same'20138,569,491'Method for preparing entecavir and intermediate used therein'20138,569,490'Intermediate and process for preparing entecavir using same'20138,513,426'Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same'20138,476,230'Insulinotropic complex using an immunoglobulin fragment'20138,426,599'Method for preparation of Montelukast acid in ionic liquid medium'20138,349,969'Method for preparing high-purity polyethyleneglycol aldehyde derivatives'20138,263,769'Process for preparing voriconazole'20128,263,084'Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate'20128,217,174'Method of preparing montelukast and intermediates used therein'20128,188,102'Amide derivative for inhibiting the growth of cancer cells'20128,163,889'Physiologically active polypeptide conjugate having prolonged in vivo half-life'20128,124,094'Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same'20128,110,665'Pharmaceutical composition comprising an immunoglobulin FC region as a carrier'20128,106,076'Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same'20128,097,706'Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein'20128,029,789'Method for the mass production of immunoglobulin constant region'20118,003,658'Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof'20117,968,316'Method for the mass production of immunoglobulin Fc region deleted initial methionine residues'20117,858,761'1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof'20107,799,907'Method for the preparation of 2′-deoxy-2′,2′-difluorocytidine'20107,736,653'Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier'20107,737,260'Protein complex using an immunoglobulin fragment and method for the preparation thereof'20107,718,399'Expression vector for secreting antibody fragment using E. coli signal sequence and method for mass-producing antibody fragment'20107,704,709'Modified human granulocyte-colony stimulating factor and process for producing same'20107,638,642'Method for the preparation of D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative'20097,625,926'P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same'20097,612,207'Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof'20097,576,219'Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same'20097,470,707'Crystalline monohydrate clopidogrel naphthalenedisulfonate and process of preparation'20087,449,580'Method of preparing thieno[3,2-c]pyridine derivatives and intermediates used therein'20087,205,394'Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same'20077,202,360'Method for preparing risperidone'20077,157,576'Crystalline acid salts of cefdinir and process for preparing cefdinir using same'20077,112,672'Process for the selective preparation of 3-(z) propenyl-cephem compound'20067,084,274'Method for the selective preparation of 3-oxo-4-aza-5α-androstane compound'20067,052,867'Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same'20067,038,050'Method for the preparation of highly pure 1-androstene derivatives'20066,936,625'Amlodipine camsylate and method for preparing thereof'20056,900,245'Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate'20056,809,188'Method of preparing clarithromycin'20046,639,068'Method of preparing highly pure cefpodoxime proxetil'20036,620,930'Process for preparing 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid'20036,605,697'Modified E. coli enterotoxin II signal peptide and a microorganism expressing a fusion protein of a said peptide and a heterologous protein'20036,528,628'Erythromycin a compounds and process for preparing the same'20036,515,116'Method of preparing form II crystals of clarithromycin'20036,506,886'Method of preparing form II crystals of clarithromycin'20036,444,796'Method of preparing form II crystals of clarithromycin'20026,423,846'High-yield method for preparing lansoprazole'20026,388,091'Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-(2-methyl-1H-imidazol-1-yl)methyl-4H-carbazol-4-one'20026,130,336'Process for preparing paclitaxel'20006,093,814'Process for preparation of cefdinir'2000

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2000–2014Patents assigned to HANMI PHARM IND CO LTD (30)· patent assignee history
2000–2019Based in Seoul, KR· patent location history
2010–2014Based in Songpa-gu, KR· patent location history
2011–2013Patents assigned to HANMI HOLDINGS CO LTD (10)· patent assignee history
2012–2017Patents assigned to LEE GWAN SUN (22)· patent assignee history
2012–2019Patents assigned to HANMI SCIENCE CO LTD (19)· patent assignee history
2012–2017Patents assigned to KWON SE CHANG (10)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
HANMI PHARM IND CO LTD302000–2014
LEE GWAN SUNself222012–2017
HANMI SCIENCE CO LTD192012–2019
HANMI HOLDINGS CO LTD102011–2013
KWON SE CHANG102012–2017
Locations
LocationPatentsSpan
Seoul, KR612000–2019
Songpa-gu, KR42010–2014